Ngm Biopharmaceuticals Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
1.54
-0.02
(-1.28%)
Volume:
2,390,830
52 week range:
0.60 - 4.69
Market Cap:
127.044M
Company Description:
NGM Biopharmaceuticals, Inc. engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. Its product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH)